Summary

U.S. Animal Health Market Growth & Trends

The U.S. animal health market size is expected to reach USD 19.77 billion by 2030, registering a CAGR of 7.97% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by growing animal population and ownership rates, increased expenditure on animals, an increasing focus on preventative animal healthcare, advances in veterinary medicine, and rising R&D investment in veterinary pharmaceuticals to launch innovative products. For instance, in November 2024, Bimeda launched MoxiSolv Injection (moxidectin), an FDA-approved parasiticide for beef and non-lactating dairy cattle, in a convenient, non-shattering 500 mL plastic bottle.

Furthermore, the industry is also driven by rising incidences of zoonotic diseases, increased livestock population, growing focus on preventive care, and growing animal expenditure. The livestock population in the U.S. has increased, with significant growth in cattle, sheep, pigs, and poultry being raised for meat production. For instance, as of January 2024, the U.S. had 87.8 million cattle and 74.97 million swine stock, according to the U.S. Foreign Agricultural Service's Livestock and Poultry: World Markets and Trade report. This substantial livestock population necessitates comprehensive veterinary care and medical interventions to maintain health and productivity.

In addition, the economic significance of the cattle industry, which contributes over USD 70 billion annually, has driven stakeholders to prioritize health management to mitigate potential losses due to diseases. The rising consumer demand for high-quality beef and dairy products and growing awareness of sustainable farming practices have also played a crucial role in adopting health management solutions for cattle. Government-backed initiatives and enhanced veterinary services in rural areas further strengthen the sector, ensuring its continued expansion.

Additionally, increasing approval of medicated feed additives significantly drives the market by improving livestock health and production efficiency. For instance, in June 2024, The FDA approved Elanco's methane-reducing feed additive, Bovaer (3-NOP), for lactating dairy cattle. Bovaer can reduce methane emissions by 30% per cow, potentially lowering emissions equivalent to removing 285,000 cars from the road annually if used by one million cows. This innovation offers financial incentives for dairy farmers through carbon markets, supporting sustainability efforts and meeting global climate goals. In partnership with dsm-Firmenich, Elanco will market Bovaer across North America, contributing to sustainable farming practices and enhancing the dairy industry’s competitiveness.

Similarly, rapid advancements in veterinary medicine present lucrative opportunities in the industry. Improvements in animal pharmaceuticals result in the development of more focused and efficient therapies for many kinds of animal illnesses and ailments. Furthermore, the demand for innovative veterinary medications is being driven by new drugs and therapies that provide better results for animals, decreased side effects, and increased efficacy. For instance, in September 2024, Merck Animal Health expanded its NOBIVAC NXT vaccine platform by launching NOBIVAC NXT FeLV, the first RNA vaccine for feline leukemia virus (FeLV). This innovative vaccine offers optimized protection against FeLV, a common feline infectious disease, and is expected to be available at veterinary clinics nationwide. Similarly, in June 2024, Bimeda launched Bimasone, the first FDA-approved generic flumethasone, used to treat inflammation and allergic conditions in horses, dogs, and cats.

U.S. Animal Health Market Report Highlights

• Based on product, the pharmaceuticals segment accounted for the highest revenue share in 2024. However, the biologics segment is anticipated to grow at the fastest CAGR over the forecast period.

• Based on animals, the production animal segment held the largest share in 2024 owing to rising incidences of zoonotic diseases, increased livestock population, growing focus on preventive care, and increased animal expenditure.

• Based on the type of vaccine, the cattle vaccine segment dominated the market in 2024, and it is expected to grow fastest with a CAGR of 9.52% over the forecast period.

• Based on the route of administration, the oral segment dominated the market with a share in 2024. This growth can be attributed to new product launches such as chewable tablets by the industry players. However, the topical segment is anticipated to grow at the fastest CAGR of 9.13% over the forecast period.

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Scope
1.1.2. Estimates And Forecast Timeline
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis
1.6.2. Global Market: CAGR Calculation
1.7. Research Scope and Assumptions
1.7.1. List of Secondary Sources
1.7.2. List of Primary Sources
1.7.3. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. U.S. Animal Health Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Drivers Analysis
3.2.1.1. Rising Prevalence of Animal Diseases
3.2.1.2. Growing Uptake Of Pet Insurance
3.2.1.3. Increase In Pet Population & Pet Humanization
3.2.2. Market Restraints Analysis
3.2.2.1. High cost of treatment
3.2.2.2. Adverse effects associated with therapies
3.2.3. Market Opportunity Analysis
3.2.4. Market Challenges Analysis
3.3. U.S. Animal Health Market Analysis Tools
3.3.1. Porter’s Analysis
3.3.1.1. Bargaining power of the suppliers
3.3.1.2. Bargaining power of the buyers
3.3.1.3. Threats of substitution
3.3.1.4. Threats from new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic and Social Landscape
3.3.2.3. Technological landscape
3.3.2.4. Environmental Landscape
3.3.2.5. Legal landscape
3.4. Covid-19 Analysis
3.5. Estimated Pet Population by key countries
Chapter 4. U.S. Animal Health Market: Animal Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. Animal Health Market Movement Analysis
4.3. U.S. Animal Health Market Size & Trend Analysis, by Animal, 2018 to 2030 (USD Million)
4.3.1. Production Animals
4.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.1.2. Poultry
4.3.1.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.1.3. Swine
4.3.1.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.1.4. Cattles
4.3.1.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.1.5. Sheep & Goats
4.3.1.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.1.6. Fish
4.3.1.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2. Companion Animals
4.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2.2. Dogs
4.3.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2.3. Cats
4.3.2.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2.4. Horses
4.3.2.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2.5. Others
4.3.2.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. U.S. Animal Health Market: Product Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. U.S. Animal Health Market Movement Analysis
5.3. U.S. Animal Health Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
5.3.1. Biologics
5.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.1.2. Vaccines
5.3.1.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.1.2.2. Attenuated Live Vaccines
5.3.1.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.1.2.3. Inactivated Vaccines
5.3.1.2.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.1.2.4. Subunit Vaccines
5.3.1.2.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.1.2.5. DNA Vaccines
5.3.1.2.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.1.2.5.2. Recombinant Vaccines
5.3.1.2.5.3. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.1.2.5.4. Autogenous Vaccines
5.3.1.2.5.5. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.1.2.5.6. Other Biologics
5.3.1.2.5.7. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.2. Pharmaceuticals
5.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.2.2. Parasiticides
5.3.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.2.3. Anti-infectives
5.3.2.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.2.4. Anti-inflammatory
5.3.2.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.2.5. Analgesics
5.3.2.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.2.6. Other Pharmaceuticals
5.3.2.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.3. Medicinal Feed Additives
5.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 6. U.S. Animal Health Market: Type of Vaccine Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. U.S. Animal Health Market Movement Analysis
6.3. U.S. Animal Health Market Size & Trend Analysis, by Type of Vaccine, 2018 to 2030 (USD Million)
6.3.1. Cattle Vaccine
6.3.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
6.3.2. Porcine Vaccine
6.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
6.3.3. Poultry Vaccine
6.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
6.3.4. Aquaculture Vaccine
6.3.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
6.3.5. Other Vaccines
6.3.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 7. U.S. Animal Health Market: Disease Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. U.S. Animal Health Market Movement Analysis
7.3. U.S. Animal Health Market Size & Trend Analysis, by Disease, 2018 to 2030 (USD Million)
7.3.1. Cattle Disease
7.3.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
7.3.2. Porcine Disease
7.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
7.3.3. Poultry Disease
7.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
7.3.4. Aquaculture Disease
7.3.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
7.3.5. Other Disease
7.3.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 8. U.S. Animal Health Market: Route of Administration Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. U.S. Animal Health Market Movement Analysis
8.3. U.S. Animal Health Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
8.3.1. Oral
8.3.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
8.3.2. Injectable
8.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
8.3.2.2. Subcutaneous
8.3.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
8.3.2.3. Intramuscular
8.3.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
8.3.2.4. Intravenous
8.3.2.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
8.3.3. Topical
8.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
8.3.4. Other
8.3.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 9. U.S. Animal Health Market: Distribution Channel Estimates & Trend Analysis
9.1. Segment Dashboard
9.2. U.S. Animal Health Market Movement Analysis
9.3. U.S. Animal Health Market Size & Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
9.3.1. Retail
9.3.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
9.3.2. E-Commerce
9.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
9.3.3. Hospital/ Clinic Pharmacy
9.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 10. Competitive Landscape
10.1. Market Participant Categorization
10.2. Company Market Position Analysis/ Heat Map Analysis
10.3. Strategy Mapping
10.3.1. Mergers & Acquisitions
10.3.2. Partnerships & Collaborations
10.3.3. Others
10.4. Company Profiles
10.4.1. Zoetis Inc.
10.4.1.1. Participant’s Overview
10.4.1.2. Financial Performance
10.4.1.3. Product Benchmarking
10.4.1.4. Strategic Initiatives
10.4.2. Ceva Santé Animale
10.4.2.1. Participant’s Overview
10.4.2.2. Financial Performance
10.4.2.3. Product Benchmarking
10.4.2.4. Strategic Initiatives
10.4.3. Merck & Co., Inc.
10.4.3.1. Participant’s Overview
10.4.3.2. Financial Performance
10.4.3.3. Product Benchmarking
10.4.3.4. Strategic Initiatives
10.4.4. Vetoquinol S.A.
10.4.4.1. Participant’s Overview
10.4.4.2. Financial Performance
10.4.4.3. Product Benchmarking
10.4.4.4. Strategic Initiatives
10.4.5. Boehringer Ingelheim Gmbh
10.4.5.1. Participant’s Overview
10.4.5.2. Financial Performance
10.4.5.3. Product Benchmarking
10.4.5.4. Strategic Initiatives
10.4.6. Elanco Animal Health Incorporated
10.4.6.1. Participant’s Overview
10.4.6.2. Financial Performance
10.4.6.3. Product Benchmarking
10.4.6.4. Strategic Initiatives
10.4.7. Virbac
10.4.7.1. Participant’s Overview
10.4.7.2. Financial Performance
10.4.7.3. Product Benchmarking
10.4.7.4. Strategic Initiatives
10.4.8. Phibro Animal Health Corporation
10.4.8.1. Participant’s Overview
10.4.8.2. Financial Performance
10.4.8.3. Product Benchmarking
10.4.8.4. Strategic Initiatives
10.4.9. Dechra Pharmaceuticals Plc
10.4.9.1. Participant’s Overview
10.4.9.2. Financial Performance
10.4.9.3. Product Benchmarking
10.4.9.4. Strategic Initiatives
10.4.10. Bimeda, Inc.
10.4.10.1. Participant’s Overview
10.4.10.2. Financial Performance
10.4.10.3. Product Benchmarking
10.4.10.4. Strategic Initiatives
10.4.11. Cargill, Incorporated.
10.4.11.1. Participant’s Overview
10.4.11.2. Financial Performance
10.4.11.3. Product Benchmarking
10.4.11.4. Strategic Initiatives
10.4.12. Aurora Pharmaceutical, Inc.
10.4.12.1. Participant’s Overview
10.4.12.2. Financial Performance
10.4.12.3. Product Benchmarking
10.4.12.4. Strategic Initiatives
10.4.13. Calier
10.4.13.1. Participant’s Overview
10.4.13.2. Financial Performance
10.4.13.3. Product Benchmarking
10.4.13.4. Strategic Initiatives
Chapter 11. Key Takeaways